Flosonics Medical among HeartX Accelerator’s selected companies for the 2023 program

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

HeartX, a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations to market, recently announced five start-ups that will participate in the 2023 Accelerator Program.

Flosonics Medical, which develops and commercializes wearable sensors improving clinical management of critically ill patients inside and outside of the hospital is named among the selected start-ups.

Congratulations to the selected companies! We are proud to share that Flosonics is an OBIO® member and an alumnus of our CAAP® , EAHN™, HealthMINT™ and WiHI programs, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Innovation Factory expands support for high-potential life science innovators by introducing medtech manufacturing funding program
Next

A4i (The App4Independence) and The Royal Ottawa Mental Health Centre Awarded Funding from OBIO’s Early Adopter Health Network to Evaluate a Digital App-based Platform for Severe Mental Illness